4.5 Article

Cost-effective osteoporosis treatment thresholds in Greece

期刊

OSTEOPOROSIS INTERNATIONAL
卷 26, 期 7, 页码 1949-1957

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s00198-015-3055-8

关键词

FRAX; Greece; Intervention thresholds; Osteoporosis; Ten-year fracture probability

资金

  1. Amgen
  2. Pfizer
  3. Leo
  4. Genesis
  5. ELPEN
  6. UniPharma
  7. VIANEX
  8. Servier
  9. Merck
  10. Eli Lilly

向作者/读者索取更多资源

A Greek-specific cost-effectiveness analysis determined the FRAX-based intervention thresholds. Assuming a willingness to pay of 30,000 [SIC], osteoporosis treatment is cost-effective in subjects under the age of 75 with 10-year probabilities for hip and major osteoporotic fractures of 2.5 and 10 %, respectively, while for older patients, the same thresholds are raised to 5 and 15 %. Introduction The purpose of this study was to determine the FRAX calculated fracture probabilities at which therapeutic intervention can be considered as cost-effective in the Greek setting. Methods A Markov cohort model was populated with Greek data, and quality-adjusted life years (QALYs) were used to calculate the cost-effective thresholds for an annual medication cost of 733.7 [SIC] by gender and age. Average FRAX-based 10-year probabilities for both major osteoporotic and hip fractures were multiplied by the model-derived relative risk at which a cost of 30,000 [SIC] for each QALY gained was observed for treatment versus to no intervention. Results A biphasic intervention threshold model is supported by our findings. Osteoporosis treatment becomes cost-effective when absolute 10-year probabilities for hip and major osteoporotic fractures reach 2.5 and 10 %, respectively, among both men and women under the age of 75. For older subjects, the proposed intervention thresholds are raised to 5 and 15 % 10-year probability for hip and major osteoporotic fractures, respectively. Conclusions Cost-effective osteoporosis treatment may be facilitated in Greece if FRAX algorithm is used to identify subjects with 10-year probabilities for hip and major osteoporotic fractures of 2.5 and 10 %, under the age of 75, while for older patients, the relevant thresholds are 5 and 15 %, respectively.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据